Clinical Trial Update: Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial exploring regorafenib plus FOLFIRI with escalated irinotecan in previously treated metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• Irinotecan (Irinotecan)
• Regorafenib (regorafenib)

Snippet

Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN